KI67, P53, NM23, and DNA Cytometry IN Bladder Cancer: Potential Markers for Detection of Recurrence?

  • Gerhard Feil
  • F. Steffen Krause
  • Andreas Zumbraegel
  • Hans W. Wechsel
  • Karl-H. Bichler

Abstract

In Germany, transitional cell carcinoma (TCC) of the urinary bladder is the eighth most common cancer.3 At present, pathological staging and grading are the most significant prognostic variables when planning treatment of TCC; however, the bladder tumor varies greatly in its biologic behavior. Up to 70% of superficial TCC (Ta/Tl) will eventually recur, while 10 to 15% will progress to muscle invasion (≥T2).4 About 50% of patients with muscle-invasive tumors subsequently develop metastases.39,41 Therefore, biological characteristics influence, to a variable extent, the incidence of recurrence, disease-free time, stage progression, and metastatic diffusion of TCC.

Keywords

Paraffin Myeloma Stein Xylene Nucleoside 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Alderisio M, Cenci M, Valli C, Russo A, Bazan V, Dardanoni G, et al: Nm23-Hl protein, DNA ploidy and S-phase fraction in relation to overall survival and disease free survival in transitional cell carcinoma of the bladder. Anticancer Res, 18:4225, 1998.PubMedGoogle Scholar
  2. 2.
    Bartoletti R, Trvaglini F, Dal Canto M, Sardi J, Piazzini M, Gacci M, et al: Prognostic role of oncogenes in bladder carcinoma: univariate and mulitvaiate analysis compared with standard prognostic parameters. Acta Urol Ital, 13:135, 1999.Google Scholar
  3. 3.
    Becker N, Wahrendorf J. Krebsatlas der Bundesrepublik Deutschland. 1981–1990. Berlin: Springer-Verlag, 1997.Google Scholar
  4. 4.
    Bichler K-H. Einführung In: Bichler K-H et al., eds. Diagnostik und Therapie des Harnblasenkarzinoms. Verlag: Einhorn-Presse, 9–13, 1998.Google Scholar
  5. 5.
    Bichler K-H, Wechsel HW, Lahme S, Wilbert DM, Strohmaier WL Die Stellung der transurethralen Elektroresektion in der Behandlung des Harnblasenkarzinoms (differenzierende transurethrale Resektion). In: Bichler K-H et al., eds. Diagnostik und Therapie des Harnblasenkarzinoms. Verlag: Einhorn-Presse, 82–91, 1998.Google Scholar
  6. 6.
    Böcking A, Schunk K, Auffermann W: Exfoliative-cytologic diagnosis of basal-cell carcinoma with the use of DNA image cytometry, Acta Cytologica, 31:143, 1987.PubMedGoogle Scholar
  7. 7.
    Böcking A, Diagnostische DNS-Zytometrie des Urothels, In: Rathert P, Roth S, eds. Urinzytologie, Berlin: Springer Verlag, 147–170, 1995.Google Scholar
  8. 8.
    Böcking A: DNA measurements, when and why? In: Wied GL et al., eds. Compendium on quality assurance, proficiency testing and workload limitations in clincal cytology, 170–188, 1995.Google Scholar
  9. 9.
    Böhm N. Einfluß der Fixierung und der Säurekonzentration auf die Feulgen-Hydrolyse bei 28°C. Histochemie, 14:201, 1968.PubMedCrossRefGoogle Scholar
  10. 10.
    Böhm N, Sprenger E, Schlüter G, Sandritter W: Proportionalitätsfehler bei der Feulgen-Hydrolyse. Histochemie, 15:194, 1968.PubMedCrossRefGoogle Scholar
  11. 11.
    Borland RN, Partin AW, Epstein JL, Brendler CB. The use of nuclear morphometry in predicting recurrence of transitional cell carcinoma. J Urol, 149:272, 1993.PubMedGoogle Scholar
  12. 12.
    Brown DC Gatter KC: Monoclonal antibody Ki-67: its use in histopathology. Histopathology, 17:489, 1990.PubMedCrossRefGoogle Scholar
  13. 13.
    Cattoretti G, Rilke F, Andreola S, D’Amato L, Delia D: p53 expression in breast cancer. Int J Cancer, 41:178, 1988.PubMedCrossRefGoogle Scholar
  14. 14.
    Cohen MB, Waldman FM, Carroll PR, Kerschmann R, Chew, Mayall BH: Comparison of five histopathological methods to assess cellular proliferation in transitional cell carcinoma of the urinary bladder. Human Pathol, 24:772, 1993.CrossRefGoogle Scholar
  15. 15.
    Feulgen R, Rosenbeck H: Mikroskopisch-chemischer Nachweis einer Nucleinsäure vom Typus der Thymonucleinsäure und die darauf beruhende elektive Färbung von Zellkulturen in mikroskopischen Präparaten. Z Physiol Chem, 135:203, 1924.CrossRefGoogle Scholar
  16. 16.
    Finlay CA, Hinds PW, Levine AJ: The p53 poto-oncogene can act as a suppressor of transformation. Cell, 57:1083, 1989.PubMedCrossRefGoogle Scholar
  17. 17.
    Friedlander ML, Hedley DW, Taylor IW: Clinical and biological significance of aneuploidy in human tumors. J Clin Path, 37:961, 1984.PubMedCrossRefGoogle Scholar
  18. 18.
    Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H: Cell cycle analysis of a cellproliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol, 133:1710, 1984.PubMedGoogle Scholar
  19. 19.
    Graumann W: Zur Standardisierung des Schiffschen Reagens. Z Wiss Mikros, 61:225–226, 1953.Google Scholar
  20. 20.
    Hansen AB, Bjerregaard B, Ovesen H, Horn T: AgNOR counts and histological grade in stage pTa bladder tumors. Histopathology, 21:591, 1992.CrossRefGoogle Scholar
  21. 21.
    Harano H, Wand C, Gao J, Uchida T: p53 tumor suppressor gene mutation and prognosis in 105 cases of bladder cancer. Nippon Hinyokika Gakkai Zasshi, 90:487, 1999.PubMedGoogle Scholar
  22. 22.
    Hruban RH, Van Der Riet P, Erozan YS, Sidransky D: Brief report: molecular biology and the early detection of carcinoma of the bladder: the case of Hubert H. Humphrey. N Engl J Med, 330:1276, 1994.PubMedCrossRefGoogle Scholar
  23. 23.
    Kimura N, Shimada N, Nomura N, Watanabe N: Isolation and characterization of a cDNA clone encoding rat nucleoside diphosphate kinase. J Biol Chem, 265:15744, 1990.PubMedGoogle Scholar
  24. 24.
    Kolkmann FW: Die Bedeutung der statischen DNA-Zytometrie in Diagnostic und Therapie. Dt Ärzteblatt, 94:747, 1997.Google Scholar
  25. 25.
    Kriiger S, Müller H: Correlation of morhometry, nuclear organizer regions, proliferating cell nuclear antigen and Ki67 antigen expression with grading and staging in urinary bladder carcinomas, Br J Urol, 75:480, 1995.CrossRefGoogle Scholar
  26. 26.
    Kuo JY, Chiang H, Chen KK, Chang LS: Immunohistochemical analysis of nm23-Hl protein in bladder cancer. Chung Hua T Hsueh Tsa Chih Taipei, 62:404, 1999.Google Scholar
  27. 27.
    Lacombe M, Wallet V, Troll H, Veron M: Functional cloning of a nucleoside diphosphate kinase from Dictyostelium discoideum, J Biol Chem, 265:10012, 1990.PubMedGoogle Scholar
  28. 28.
    Lane DP, Crawford LV: T antigen is bound to a host protein in SV-40 transformed cells. Nature, 278:261, 1979.PubMedCrossRefGoogle Scholar
  29. 29.
    Lane DP, Benchimol S: p53: oncogene or anti-oncogene. Genes and Dev, 4:1, 1990.PubMedCrossRefGoogle Scholar
  30. 30.
    Leone A, Flatow U, King CR, Sandeen MA, Margulies IMK, Liotta LA, et al: Reduced tumor incidence, metastatic potential, and cytokine responsiveness of nm23-transfected melanoma cells. Cell, 65:25, 1991.PubMedCrossRefGoogle Scholar
  31. 31.
    Lipponen PK, Eskelinen MJ, Jauhiainen K, Terho R, Nordling S: Proliferation indices as independent prognostic factors in papillary Ta-T1 transitional cell bladder tumors. Br J Urol, 72:451, 1993.PubMedCrossRefGoogle Scholar
  32. 32.
    Mansour P, Crocker J, Newman J: Lack of prognostic value of NOR enumeration in transitional cell carcinoma of the bladder. Arch Pathol Lab Med, 114:1261, 1990.PubMedGoogle Scholar
  33. 33.
    Nenning H, Raßler J, Minh DH, Stolzenburg JU: The value of DNA cytometry in transitional cell carcinoma of the urinary bladder. Gen Diagn Pathol, 143: 231, 1997.PubMedGoogle Scholar
  34. 34.
    Okamura K, Miyake K, Koshikawa K, Asai J: Growth fractions of transitional cell carcinomas of the bladder defined by monoclonal antibody KI67. J Urol, 144: 875, 1990.PubMedGoogle Scholar
  35. 35.
    Ooms ECM, Kurver PHJ, Veldhuizen RW, Alons CL, Boon ME: Morphometric grading of bladder tumors in comparison with histologic grading by pathologists. Hum Pathol, 14:144, 1983.PubMedCrossRefGoogle Scholar
  36. 36.
    Pfister C, Flaman JM, Martin C, Grise P, Frebourg T: Selective detection of inactivating mutations of the tumor suppressor gene p53 in bladder tumors. J Urol, 161:1973, 1999.PubMedCrossRefGoogle Scholar
  37. 37.
    Pinhasi-Kimhi O, Michalovitz D, Ben-Zeev A, Oren M: Specific interaction between the p53 cellular tumor antigen and major heat shock proteins. Nature, 320:182, 1986.PubMedCrossRefGoogle Scholar
  38. 38.
    Sarnow PP, Ho YS, Williams J, Levine AJ: Adenovirus E1b-58kD tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kD cellular protein in transformed cells. Cell, 28:387, 1982.PubMedCrossRefGoogle Scholar
  39. 39.
    Sauter G, Moch H, Carroll P, Kerschmann R, Mihatsch MJ, Waldmann FM: Chromosome-9 loss detected by fluorescence in situ hybridisation in bladder cancer. Int J Cancer, 64:99, 1995.PubMedCrossRefGoogle Scholar
  40. 40.
    Sawhney N, Hall PA: Ki-67 — structure, function, and new antibodies. J Pathol, 168:161, 1992.PubMedCrossRefGoogle Scholar
  41. 41.
    Schalken JA Debrruyne MJ: Prognostic indicators of bladder cancer. Cur Opinon Urol, 5:272, 1995.Google Scholar
  42. 42.
    Schapers R, Ploem-Zajer JJ, Pauwels RP, Smeets AW, Van-Den-Brandt PA, Tanke HJ, et al: Image cytometry DNA analysis in transitional cell carcinoma of the bladder. Cancer, 72:182, 1993.PubMedCrossRefGoogle Scholar
  43. 43.
    Scott R J, Hall PA, Haldane JS, Price Y, Van Noorden S: A comparison of immunhistochemical markers of cell proliferation with experimentally determined growth fraction. J Pathol, 165:173, 1991.PubMedCrossRefGoogle Scholar
  44. 44.
    Seckinger D, Sugarbaker E, Frankfurt O: DNA content in human cancer. Application in pathology and clinical medicine. Arch Path Lab Med, 113:619, 1989.PubMedGoogle Scholar
  45. 45.
    Stahl JA, Leone A, Rosengard AM, Porter L, King CR, Steeg PS: Identification of a second human nm23 gene. Cancer Research, 51:445, 1991.PubMedGoogle Scholar
  46. 46.
    Stavropoulos NE, Ioackim-Velogianni E, Hastazeris K, Kitsiou E, Stefanski S, Agnantis N: Growth fractions in bladder cancer defined by Ki67: association with cancer grade, category and recurrence rate of superficial lesions. Br J Urol, 72:736, 1993.PubMedCrossRefGoogle Scholar
  47. 47.
    Steeg PS, Bevilacqua G, Kopper L, Thorgeirsson UP, Talmadge JE, Liotta LA, et al: Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst, 80:200, 1988.PubMedCrossRefGoogle Scholar
  48. 48.
    Steeg PS, Bevilacqua G, Pozatti R, Liotta LA, Sobel ME: Altered expression of nm23, a gene associated with low tumor metastatic potential, during adenovirus 2 Ela inhibition of experimental metastasis. Cancer Res, 48:6550, 1988.PubMedGoogle Scholar
  49. 49.
    Urano T, Takamiya K, Furukawa K, Shiki H: Molecular cloning and functional expression of the second mouse nm23/NDP kinase gene, nm23-M2. Fed Euro Biochem Soc, 309:358, 1992.CrossRefGoogle Scholar
  50. 50.
    Urano T, Furukawa K, Shiku H: Expression of nm23/NDP kinase proteins on the cell surface. Oncogene, 8:1371, 1993.PubMedGoogle Scholar
  51. 51.
    Van Den Berg FM, Tigges AJ, Schipper ME, Den-Hartog-Jager FC, Kroes WG, Walboomers JM: Expression of the nuclear oncogene p53 in colon tumors. J Pathol, 157:193, 1988.CrossRefGoogle Scholar
  52. 52.
    Van Velthoven R, Petein M, Oosterlinck WJ, Zandona C, Zlotta A, Ven Der Meijden APM, et al: Image cytometry determination of ploidy level, proliferative activity, and nuclear size in a series of 314 transitional bladder cell carcinoma. Human Pathol, 26:3, 1995.CrossRefGoogle Scholar
  53. 53.
    Vindelov LL, Christensen IJ, Engelholm SA, Guldhammer BH, Hojgaard K, Sorensen BL, et al: Prognostic significance of DNA content in bladder cancer based on flow cytometric analysis of 249 transitional cell carcinomas. Cytometry, 22:93, 1995.PubMedCrossRefGoogle Scholar
  54. 54.
    Vorreuther R, Hake R, Heidenreich A, Thiele J, Engelmann U: Der Wert immunhistochemischer Marker (PCNA, Ki67, 486p und p53) in der Abschätzung des Rezidivrisikos oberflächlicher Blasenkarzinome. Akt Urol, 28:109, 1997.CrossRefGoogle Scholar
  55. 55.
    Wright C, Thomas D, Mellon K, Neal DE, Wilson Horne CH: Expression of retinoblastoma gene product and p53 protein in baldder carcinoma: correlation with Ki67 index. Br J Urol, 75:173, 1995.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2003

Authors and Affiliations

  • Gerhard Feil
    • 1
  • F. Steffen Krause
    • 1
  • Andreas Zumbraegel
    • 1
  • Hans W. Wechsel
    • 1
  • Karl-H. Bichler
    • 1
  1. 1.Department of UrologyEberhard-Karls-University of TübingenTübingenGermany

Personalised recommendations